How much funding has Achelios Therapeutics raised?

Achelios Therapeutics has disclosed $3.5M raised across 2 rounds.

Where is Achelios Therapeutics headquartered?

Achelios Therapeutics is headquartered in Chapel Hill, US.

Achelios Therapeutics

Chapel Hill, US · Founded 2012 · Delaware corporation

Find your way into Achelios Therapeutics

467 people in our graph share verified history with the Achelios Therapeutics team — schools, employers, funds. One of them is your warm intro.

Qiang Xuunlockedknows Crist J. Frangakis · together at Bayer Pharmaceuticals (overlapped)

×7knows the team · via Bayer Pharmaceuticals

×4knows the team · via GlaxoWellcome

Achelios Therapeutics develops therapies for chronic pain conditions including temporomandibular joint pain, migraine, and arthritis-related joint pain through repurposed and reformulated drug candidates. The company addresses unmet medical needs in chronic pain that have been underserved by larger pharmaceutical firms.

Biotech Healthtech Medical Devices

Founders & leadership

Crist J. Frangakis President & CEOCrist J. Frangakis is an executive officer and director at Achelios Therapeutics. He brings experience in pharmaceutical R&D licensing and business development, with background in cardiovascular and endocrine therapeutics.

Board

Ron VeredBoard director

Jerry RosenblattBoard director

William DickieBoard director

William BauerBoard director

Reported raises · per SEC filings

Form D private placements

$3.5M disclosed across 2 rounds · 2012–2016

▶$350KraisedApr 2016 · 2 investors · Other Health Care

Rule 506(b)

Officers, directors & promoters on the filing

Ron VeredDirector
Crist J. FrangakisExecutive Officer, Director
Jerry RosenblattDirector

Offering amount: $2M
Amount sold: $350K
First sale: Apr 2016
Incorporated: Corporation, Delaware, 2012
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$3.2MraisedMar 2014 · 33 investors · Pharmaceuticals

Rule 506(b)

Officers, directors & promoters on the filing

Crist J. FrangakisExecutive Officer, Director
Ron VeredDirector
William DickieDirector
William BauerDirector

Offering amount: $4.3M
Amount sold: $3.2M
Minimum investment: $10K
Proceeds to insiders: $700K
First sale: Feb 2012
Incorporated: Corporation, Delaware, 2012
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 9

by search overlap

Elicio8 shared keywordsElicio Therapeutics is a biopharmaceutical company focused on developing therapeutic treatments.

Xilio Therapeutics8 shared keywordsXilio Therapeutics is a clinical-stage biotechnology company developing masked immuno-oncology therapies that use protein engineering to remain inactive until activated by tumor-specific proteases within the tumor microenvironment. Its approach aims to achieve durable efficacy for cancer patients while avoiding the severe systemic side effects of conventional immuno-oncology agents.

Lexeotx8 shared keywordsLexeo is a clinical-stage genetic medicine company developing gene therapies that target the genetic causes of cardiovascular diseases. Based in New York City, it focuses on treatments for heart health and other genetic diseases regardless of prevalence.

Alloy6 shared keywordsAlloy provides drug discovery services and platform technologies across genetic medicines, TCR mimics, and cell therapies, supporting pharmaceutical partners in developing novel treatments.

Aulos Bioscience6 shared keywordsAulos develops an immune-activating monoclonal antibody therapeutic for cancer, using AI to design an antibody targeting the IL-2 portion that interacts with the CD25 receptor to shift IL-2 activity toward immune activation. Its lead investigational candidate, imneskibart, is in a Phase 1/2 clinical trial for solid tumor cancers including melanoma and renal cell carcinoma.

Calliotx6 shared keywordsCallio Therapeutics develops next-generation dual-payload antibody-drug conjugates (ADCs) with differentiated payload and linker technologies for targeted cancer treatment. The company's lead program is a dual-payload HER2-targeted ADC designed to deliver drug combinations to tumor cells.

Seelos Therapeutics6 shared keywords

Aligos Therapeutics5 shared keywordsAligos is a clinical-stage biotechnology company developing therapeutics for liver and viral diseases, including chronic hepatitis B virus (HBV) infection and MASLD/MASH. Its pipeline targets conditions that are major causes of liver cancer and liver-related illness worldwide.

Alexion Pharmaceuticals5 shared keywordsAlexion is a biopharmaceutical company focused on research and development of treatments for rare diseases, serving rare disease patients and their families worldwide.

Companies competing with Achelios Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.

Frequently asked questions

What does Achelios Therapeutics do?: Achelios Therapeutics develops therapies for chronic pain conditions including temporomandibular joint pain, migraine, and arthritis-related joint pain through repurposed and reformulated drug candidates. The company addresses unmet medical needs in chronic pain that have been underserved by larger pharmaceutical firms.
How much funding has Achelios Therapeutics raised?: Achelios Therapeutics has disclosed $3.5M raised across 2 rounds.
Where is Achelios Therapeutics headquartered?: Achelios Therapeutics is headquartered in Chapel Hill, US.